Be Bio is looking to hire a Head of B Cell Therapeutics for Oncology, reporting directly to Senior Vice President of Pipeline Research. This is a unique opportunity to build both the strategy and team in this critical therapeutic area that is targeted to produce multiple programs and multiple modalities given the versatility of our platform. This role will have the chance to build a broad, deep research pipeline in Oncology with transformative potential to impact patients’ lives.

This highly visible leader will spearhead the development of our discovery-stage B cell therapeutics platform for oncology and serve as a core member of the Research Scientific Leadership team, making significant contributions to scientific direction and strategy.

Role & Responsibilities:

  • You will be responsible for project team leadership and will help to expand and lead the drug discovery teams to enable successful execution of Oncology programs. Your teams will be responsible for both establishing the core assays by which therapeutic candidates are evaluated and then applying these methods to specific candidates. 
  • You will have oversight and responsibility for all required preclinical data incorporated into development candidate nomination and IND filings.
  •  
  •  
  • Leverage and expand knowledge of current and emerging oncology clinical landscape to inform target selection as well as the translational and clinical strategies for existing programs.
  • Work with senior leadership to develop, refine, and implement the overall targeted oncology research strategy with a specific focus on selection of development candidates (DC).
  • Works closely with other key stakeholders to define product specifications from desirable target product profiles
  • Pioneers the design, creation, sourcing, and execution of all necessary capabilities and know-how in a hands-on manner
  • Build, coach, develop, and retains a leading team of high-performing B cell genetic engineers (scientists & RAs), cancer biologists that can realize the company’s goals in a rigorous and efficient science-first manner
  • Direct and prioritize efforts at both Contract Research Organizations and in Be Bio labs as needed to address key questions and drive progression within aggressive timelines
  • Leads development of assays that deeply profile the properties of B cells engineered to produce anti-tumor biologics
  • Ultimately responsible for delivery of R&D grade and scale material that meets product candidate specifications for preclinical testing in PDX and CDX animal models
  • Represent the program team in discussions with management, scientific advisors, external stakeholders, and potential partners
  • Consistently strives to improve capabilities with cutting edge techniques and tools

Critical Factors for Success

Scientific Vision & Strategy: Ability to create a compelling vision for the Oncology Research organization, formulate and implement scientific strategies to drive the organization forward, and establish purpose and direction for research teams

Leadership & People Strategy: Ability to lead diverse teams to produce exceptional results in a dynamic, fast-paced, matrixed environment.  Deep understanding of research team dynamics/effectiveness.  Significant ability to design and build high-performing teams as well as develop future research leaders.

Entrepreneurial: Ability to thrive in a fast-paced, dynamic environment that is building infrastructure/operating efficiency/capability while delivering significant results on challenging goals and objectives.

Dealing with Ambiguity: Able to individually and with others carve through situations with unclear answers/solutions or uncertain paths and create positive change/momentum.

 

Who are we seeking?

  • PhD in Immunology, Cancer Biology, or equivalent
  • 4+ years of outstanding experience in leadership roles within biotech or pharma companies that are developing cell and/or gene therapies discovery stage programs for immune oncology
  • Demonstrable track record in cell engineering, especially primary human immune cells, using cutting edge genomic editing tools in a drug development environment
  • Expertise in advanced cell culture techniques, including familiarity with large-scale compatible manufacturing techniques and industry best practices
  • Demonstrated know-how with viral vectors and gene editing methods for use in ex vivo cell engineering
  • Familiarity with cutting edge standards and including analytical methodologies for cell medicine development highly desirable
  • Background in B cell biology/immunology highly desirable

About us

 

Be Biopharma is pioneering a new class of medicines, unleashing the power of B cells to create the new field of Engineered B Cell Medicines.  B cells are the body’s protein producing factories, most widely known for making antibodies.  Our leading B cell therapy platform, developed by the top scientific KOLs in the field and with strong IP protection, harnesses this capability to engineer B cells to produce any protein with potential therapeutic application.  This creates a unique opportunity to rapidly design and develop a broad portfolio of disease changing products (our platform affords ready swapping in new genes for different disease indications) and to significantly scale the company to realize substantial value in a short period of time.

 

Importantly, and in contrast to other cell therapy modalities, Engineered B Cells engraft naturally (and thus are not expected to require preconditioning chemotherapy).  They are also “naturally allogeneic”, and we expect most or all of our portfolio to be “off-the-shelf” medicines.  We have a rich pipeline of initial medicines under development in Oncology and Severe Genetic Disease, and we will subsequently expand to other important indications (e.g. Infectious Disease, Autoimmune Disease, etc).

 

Our Cambridge-based team is led by highly experienced, mission-driven executives all of whom are experienced cell therapy veterans who played key roles in developing several of today’s most impactful marketed gene and cell therapies.  The team is rapidly expanding, with 40 employees joining in the first half of 2022.  We are making major strides in our proof-of-concept studies for our lead programs in Rare Disease and Oncology, which are on track for near-term clinical development. Be Biopharma was founded in 2020 and closed a $130 million Series B financing in April of 2022, bringing the total investment in the Company to over $180 million. The proceeds will advance Be Bio’s proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates toward the clinic. The Series B was led by ARCH Venture Partners and joined by Bristol Myers Squibb and other new investors, alongside existing leading investors that include Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and Takeda Ventures.

 

Culture

The beating heart of Be Bio is our People and together we are building a culture driven by purpose, passion, and that’s full of character.  We are “all-in” as we align ourselves with patients who need our medicines, and we embrace the highest standards of transparency, excellence, candor, collaboration, and team-based science with a shared ownership of company milestones and successes. 

 

Our commitment to our team members is to deliver a compelling, dynamic work experience that enables them to continually stretch, grow, and learn, that enriches their lives, that fosters a sense of belonging and community, and that goes above and beyond to support them in big, meaningful ways in both their personal and professional lives.  Be Bio is a team that works hard, plays hard, and supports each other on our shared journey to get transformative medicines to patients who need them. 

 

 

About Be Biopharma

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb and Takeda Ventures. Since our founding, Be Bio’s investors have committed over $180 million to enable the Company to re-imagine medicine based on the power of B cell therapy. For more information, please visit us at Be.Bio and our LinkedIn page.

Culture

The beating heart of Be Bio is our People and together we are building a culture driven by purpose, passion, and that’s full of character.  We are “all-in” as we align ourselves with patients who need our medicines, and we embrace the highest standards of transparency, excellence, candor, collaboration, and team-based science with a shared ownership of company milestones and successes. 

Our commitment to our team members is to deliver a compelling, dynamic work experience that enables them to continually stretch, grow, and learn, that enriches their lives, that fosters a sense of belonging and community, and that goes above and beyond to support them in big, meaningful ways in both their personal and professional lives.  Be Bio is a team that works hard, plays hard, and supports each other on our shared journey to get transformative medicines to patients who need them. 

 

 

 

 

Apply for this Job

* Required
resume chosen  
(File types: pdf, doc, docx, txt, rtf)
cover_letter chosen  
(File types: pdf, doc, docx, txt, rtf)


Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

As set forth in Be Biopharma, Inc.’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.


Form CC-305

OMB Control Number 1250-0005

Expires 05/31/2023

Voluntary Self-Identification of Disability

Why are you being asked to complete this form?

We are a federal contractor or subcontractor required by law to provide equal employment opportunity to qualified people with disabilities. We are also required to measure our progress toward having at least 7% of our workforce be individuals with disabilities. To do this, we must ask applicants and employees if they have a disability or have ever had a disability. Because a person may become disabled at any time, we ask all of our employees to update their information at least every five years.

Identifying yourself as an individual with a disability is voluntary, and we hope that you will choose to do so. Your answer will be maintained confidentially and not be seen by selecting officials or anyone else involved in making personnel decisions. Completing the form will not negatively impact you in any way, regardless of whether you have self-identified in the past. For more information about this form or the equal employment obligations of federal contractors under Section 503 of the Rehabilitation Act, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

How do you know if you have a disability?

You are considered to have a disability if you have a physical or mental impairment or medical condition that substantially limits a major life activity, or if you have a history or record of such an impairment or medical condition.

Disabilities include, but are not limited to:

  • Autism
  • Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, or HIV/AIDS
  • Blind or low vision
  • Cancer
  • Cardiovascular or heart disease
  • Celiac disease
  • Cerebral palsy
  • Deaf or hard of hearing
  • Depression or anxiety
  • Diabetes
  • Epilepsy
  • Gastrointestinal disorders, for example, Crohn's Disease, or irritable bowel syndrome
  • Intellectual disability
  • Missing limbs or partially missing limbs
  • Nervous system condition for example, migraine headaches, Parkinson’s disease, or Multiple sclerosis (MS)
  • Psychiatric condition, for example, bipolar disorder, schizophrenia, PTSD, or major depression

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.